A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study

被引:27
|
作者
Kapadia, Shashi N. [1 ,2 ]
Griffin, Judith L. [1 ,3 ]
Waldman, Justine [3 ]
Ziebarth, Nicolas R. [4 ]
Schackman, Bruce R. [2 ]
Behrends, Czarina N. [2 ]
机构
[1] Weill Cornell Med, Dept Med, New York, NY 10065 USA
[2] Weill Cornell Med, Dept Populat Hlth Sci, New York, NY USA
[3] REACH Med, Ithaca, NY USA
[4] Cornell Univ, Dept Policy Anal & Management, Ithaca, NY USA
关键词
buprenorphine; harm reduction; primary care; qualitative; opioid use disorder; TREATMENT RETENTION; TREATMENT OUTCOMES; BUPRENORPHINE; PROFESSIONALS; BARRIERS;
D O I
10.1007/s11606-020-06409-6
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Stigma is a barrier to the uptake of buprenorphine to treat opioid use disorder. Harm reduction treatment models intend to minimize this stigma by organizing care around non-judgmental interactions with people who use drugs. There are few examples of implementing buprenorphine treatment using a harm reduction approach in a primary care setting in the USA. Methods We conducted a qualitative study by interviewing leadership, staff, and external stakeholders at Respectful, Equitable Access to Compassionate Healthcare (REACH) Medical in Ithaca, NY. REACH is a freestanding medical practice that provides buprenorphine treatment for opioid use disorder since 2018. We conducted semi-structured interviews with 17 participants with the objective of describing REACH's model of care. We selected participants based on their position at REACH or in the community. Interviews were recorded, transcribed, and analyzed for themes using content analysis, guided by the CDC Evaluation Framework. Results REACH provided buprenorphine, primary care, and mental health services in a low-threshold model. We identified three themes related to delivery of buprenorphine treatment. First, an organizational mission to provide equitable and low-stigma healthcare, which was a key to organizational identity. Second, a low-threshold buprenorphine treatment approach that was critical, but caused concern about over-prescribing and presented logistical challenges. Third, creation and retention of a harm reduction-oriented workforce by offering value-based work and by removing administrative barriers providers may face elsewhere to providing buprenorphine treatment. Conclusions A harm reduction primary care model can help reduce stigma for people who use drugs and engage in buprenorphine treatment. Further research is needed to evaluate whether this model leads to improved patient outcomes, can overcome community stakeholder concerns, and is sustainable.
引用
收藏
页码:1898 / 1905
页数:8
相关论文
共 50 条
  • [1] A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study
    Shashi N. Kapadia
    Judith L. Griffin
    Justine Waldman
    Nicolas R. Ziebarth
    Bruce R. Schackman
    Czarina N. Behrends
    Journal of General Internal Medicine, 2021, 36 : 1898 - 1905
  • [2] Examining the Primary Care Experience of Patients With Opioid Use Disorder: A Qualitative Study
    Incze, Michael A.
    Chen, David
    Galyean, Patrick
    Kimball, Elisabeth R.
    Stolebarger, Laura
    Zickmund, Susan
    Gordon, Adam J.
    JOURNAL OF ADDICTION MEDICINE, 2023, 17 (04) : 401 - 406
  • [3] A novel approach to treating adolescents with opioid use disorder in pediatric primary care
    Levy, Sharon
    Mountain-Ray, Shannon
    Reynolds, Jason
    Mendes, Steven J.
    Bromberg, Jonas
    SUBSTANCE ABUSE, 2018, 39 (02) : 173 - 181
  • [4] Implementing buprenorphine for opioid use disorder in veterans health administration primary care: a qualitative analysis
    Lott, Aline
    Danner, Anissa N.
    Malte, Carol A.
    Salameh, Hope A.
    Bachowski, Diana
    Gordon, Adam J.
    Hagedorn, Hildi J.
    Frost, Madeline C.
    Williams, Emily C.
    Saxon, Andrew J.
    Trim, Ryan S.
    Hawkins, Eric J.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2025, 20 (01):
  • [5] Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings
    Madeline C. Frost
    Elena M. Soyer
    Carol E. Achtmeyer
    Eric J. Hawkins
    Joseph E. Glass
    Kevin A. Hallgren
    Emily C. Williams
    Addiction Science & Clinical Practice, 18
  • [6] Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings
    Frost, Madeline C.
    Soyer, Elena M.
    Achtmeyer, Carol E.
    Hawkins, Eric J.
    Glass, Joseph E.
    Hallgren, Kevin A.
    Williams, Emily C.
    ADDICTION SCIENCE & CLINICAL PRACTICE, 2023, 18 (01)
  • [7] Perceptions of Primary Care Among Women in Treatment for Opioid Use Disorder: A Qualitative Study
    Short, Vanessa L.
    Spritzer, Kathleen
    Jaffe, Gregory A.
    Sabitsky, Matt
    Abatemarco, Diane
    Mclaughlin, Kim
    Hand, Dennis J.
    Gannon, Meghan
    SUBSTANCE USE & ADDICTION JOURNAL, 2024, 45 (04): : 698 - 705
  • [8] Why use group visits for opioid use disorder treatment in primary care? A patient-centered qualitative study
    Sokol, Randi
    Albanese, Chiara
    Chaponis, Deviney
    Early, Jessica
    Maxted, George
    Morrill, Diana
    Poirier, Grace
    Puopolo, Fran
    Schuman-Olivier, Zev
    SUBSTANCE ABUSE, 2018, 39 (01) : 52 - 58
  • [9] Attitudes of Black American Christian church leaders toward Opioid Use Disorder, overdoses, and harm reduction: a qualitative study
    Dankwah, Akosua B.
    Siegrist Jr, Richard B.
    Wilson, Ira B.
    McKenzie, Michelle
    Rich, Josiah D.
    FRONTIERS IN PSYCHIATRY, 2024, 15
  • [10] Impact of Stigma on Clinician Training for Opioid Use Disorder Care: A Qualitative Study in a Primary Care Learning Collaborative
    Klusaritz, Heather
    Bilger, Andrea
    Paterson, Emily
    Summers, Courtney
    Barg, Frances K.
    Cronholm, Peter F.
    Saine, M. Elle
    Sochalski, Julie
    Doubeni, Chyke A.
    ANNALS OF FAMILY MEDICINE, 2023, 21 : S31 - S38